Sort   by:  
 Page size 
MetabolomicsOxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients' tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell line...
2023-06-27 | MTBLS3342 | MetaboLights
MetabolomicsMetabolic adaptations in an endocrine-related breast cancer mouse model unveil potential markers of tumor response to hormonal therapy
Not available
ORGANISM(S): Mus musculus 
ST001984 | MetabolomicsWorkbench
GenomicsGenome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer
The estrogen receptor alpha (ERa) drives the growth of two-thirds of all breast cancers. Endocrine therapy impinges on estrogen-induced ERa activation to block tumor growth. However, half of ERa-positive breast cancers are tolerant or acquire endocrine therapy resistance. Here we demonstrate that br...
ORGANISM(S): Homo sapiens 
2013-05-01 | E-GEOD-37323 | biostudies-arrayexpress
TranscriptomicsExpression profile of the endocrine therapy resistant breast cancer cells LTED depleted of PBX1 or treated with the gamma-secretase inhibitor MRK003
Analysis of the response to PBX1 deprivation either using an siRNA approach or using a chemicalcompound indirectly targeting it. Deprivation of PBX1 is hypothesized to be essential for the growth of endocrine therapy resistant breast cancer cells (LTED) Total RNA was obtained from cells treated with...
ORGANISM(S): Homo sapiens 
2013-05-01 | E-GEOD-36928 | biostudies-arrayexpress
TranscriptomicsMolecular changes in lobular breast cancers in response to endocrine therapy
Invasive lobular cancer (ILC) accounts for approximately 10-15% of breast carcinomas and although it responds poorly to neoadjuvant chemotherapy, it appears to respond well to endocrine therapy. Pre- and on-treatment (after 2 weeks and 3 months) biopsies and surgical samples were obtained from 14 ...
ORGANISM(S): Homo sapiens 
2014-08-11 | E-GEOD-55374 | biostudies-arrayexpress
ProteomicsCoordinate Enhancer Reprogramming by GATA3 and AP1 Promotes Phenotypic Plasticity to Achieve Breast Cancer Endocrine Resistance
Phenotypic plasticity has emerged as an important mechanism of therapy resistance in cancers, yet the underlying molecular mechanisms remain unclear. Using an established breast cancer cellular model for endocrine resistance, we show that hormone resistance is associated with enhanced phenotypic pla...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2019-05-24 | MSV000083857 | MassIVE
TranscriptomicsA phase II study of adding the multikinase sorafenib to existing endocrine therapy in patients with metastatic ER-positive breast cancer.
Growth factor signaling and angiogenesis may promote endocrine-resistance in breast cancer and blocking these pathways can overcome resistance in preclinical models. We conducted a phase-II study of adding the VEGFR/Ras/Raf/MAPK inhibitor sorafenib to endocrine therapy in metastatic ER-positive bre...
ORGANISM(S): Homo sapiens 
2012-09-13 | E-GEOD-40837 | biostudies-arrayexpress
TranscriptomicsRNA sequencing of endocrine resistant breast cancer
*** This submission includes RNA data, with DNA files available under a different accession number*** Purpose: Endocrine therapy resistance remains the greatest challenge for treating hormone receptor positive breast cancer patients. We aim to identify molecular mechanisms underlying endocrine ther...
ORGANISM(S): Homo sapiens 
2022-09-01 | E-MTAB-9917 | biostudies-arrayexpress
TranscriptomicsSRC1 gene regulation in endocrine resistant breast cancer cells
The development of breast cancer resistance to endocrine therapy results from an increase in cellular plasticity leading to the development of a steroid independent tumour. The p160 steroid coactivator protein SRC-1, through interactions with developmental proteins and other non-steroidal transcrip...
ORGANISM(S): Homo sapiens 
2012-01-11 | E-GEOD-28645 | biostudies-arrayexpress
GenomicsNCTN: Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positive Advanced Breast Cancer (CALGB-40503)
NCTN: Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positive Advanced Breast Cancer (CALGB-40503)
PRJNA1367607 | ENA
Sort   by:  
 Page size